Wolf Herve Fridman
Overview
Explore the profile of Wolf Herve Fridman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu X, Vano Y, Su X, Verkarre V, Sun C, Cheng W, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39848689
Background: Endogenous retrovirus (ERV) elements are genomic footprints of ancestral retroviral infections within the human genome. While the dysregulation of ERV transcription has been linked to immune cell infiltration in...
2.
Lu X, Vano Y, Su X, Helleux A, Lindner V, Mouawad R, et al.
Cell Rep Med
. 2023 Nov;
4(11):101287.
PMID: 37967556
The efficacy of immune checkpoint inhibitors varies in clear-cell renal cell carcinoma (ccRCC), with notable primary resistance among patients. Here, we integrate epigenetic (DNA methylation) and transcriptome data to identify...
3.
Clifton G, Rothenberg M, Ascierto P, Begley G, Cecchini M, Eder J, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37290925
Checkpoint inhibitors represent an effective treatment approach for a variety of cancers through their inhibition of immune regulatory pathways within the tumor microenvironment (TME). Unfortunately only a minority of patients...
4.
Tiwari A, Oravecz T, Dillon L, Italiano A, Audoly L, Fridman W, et al.
Front Immunol
. 2023 Apr;
14:1084887.
PMID: 37033994
Background: The immune cell topography of solid tumors has been increasingly recognized as an important predictive factor for progression of disease and response to immunotherapy. The distribution pattern of immune...
5.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35640928
Background: The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a 'real-world setting'. We conducted...
6.
Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32819974
Background: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential...
7.
Fridman W, Teillaud J
Med Sci (Paris)
. 2019 May;
35(4):367-373.
PMID: 31038116
No abstract available.
8.
Casuscelli J, Vano Y, Fridman W, Hsieh J
Kidney Cancer
. 2018 Oct;
1(1):3-13.
PMID: 30334000
Renal cell carcinoma (RCC) encompasses a wide spectrum of morphologically and molecularly distinct (>10) cancer subtypes originated from the kidney epithelium. Metastatic RCC (mRCC) is lethal and refractory to conventional...
9.
Fridman W
Bull Cancer
. 2017 Jan;
103 Suppl 1:S122-S126.
PMID: 28057174
HISTORY OF IMMUNOTHERAPY. PARADIGM CHANGE?: Born at the dawn of the 20th century with W.B. Coley's intratumoral injections of bacteria, cancer immunotherapy was built on the corpus of the immune...
10.
Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S, et al.
Oncoimmunology
. 2016 Oct;
5(9):e1214790.
PMID: 27757313
Malignant cells succumbing to some forms of radiation therapy are particularly immunogenic and hence can initiate a therapeutically relevant adaptive immune response. This reflects the intrinsic antigenicity of malignant cells...